Glutamate deprivation or blockade with mGluR1-antagonist results in significantly decreased cell proliferation, migration, and invasion of prostate cancer cells, leading to apoptotic cell death, demonstrating a potentially important role of glutamate pathway for prostate cancer growth [62]. Here, GRM1 is linked to prostate cancer.